Centre for Clinical Practice – Surveillance Programme

Clinical guideline
CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care

Publication date
January 2012

Surveillance report for GE
February 2014

Key findings

<table>
<thead>
<tr>
<th>Potential impact on guidance</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evidence from Evidence Update</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Feedback from Chair of the Evidence Update Advisory Group</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Anti-discrimination and equalities considerations</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>No update</td>
<td>Rapid update</td>
<td>Standard update</td>
</tr>
<tr>
<td>✓</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CG137 – Epilepsy, Surveillance review decision, February 2014
1 of 4
Surveillance review of CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care

Background information
Guideline issue date: 2012
2 year review: 2014
NCC: NCGC

Current two year surveillance review
1. The Evidence Update on CG137: Epilepsy (expected publication date: February 2014) was used as the primary source of evidence for this surveillance review (search dates: June 2010 –September 2013). Clinical feedback on the surveillance decision for the guideline was obtained from the Chair of the Evidence Update Advisory Group.

2. The Evidence Update indicates that there is currently insufficient new evidence to invalidate the majority of the guideline recommendations. However, the Evidence Update has one area: adjunctive treatment for refractory focal epilepsy with new evidence which may impact current guideline recommendations. The 3 trials regarding perampanel which were identified in the Evidence Update, were not head to head trials, and it is unlikely that they would alter the conclusions of the existing model that supports the current recommendations. Hence an update in this area is not worthwhile at this time. A summary of the evidence is provided in the Evidence Update.

3. The Chair of the Evidence Update Advisory Group (and member of the original Guideline Development Group) felt that CG137 Epilepsy the majority of the guideline is up to date but the guideline could benefit from updating around adjunctive treatment for refractory focal epilepsy.
On-going Research
4. Not applicable.

Anti-discrimination and equalities considerations
5. None identified.

Implications for other NICE programmes
6. None identified.

Conclusion
7. Through the surveillance review of CG137, no new evidence which may potentially change the direction of guideline recommendations was identified.

Surveillance recommendation
8. GE is asked to consider the proposal to not update the guideline at this time. GE are asked to note that as a 2 year surveillance review this ‘no to update’ proposal will not be consulted on.

Mark Baker – Centre Director
Sarah Willett – Associate Director
Katy Harrison– Technical Analyst

Centre for Clinical Practice
February 2014
References